Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)

NCT07441395 is registered in ClinicalTrials.gov with Corvus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07441395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07441395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
Lead sponsor
Corvus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 28, 2026
Completion date
September 30, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis eczema, eczema, eczema, atopic